Randell E W, Parkes J G, Olivieri N F, Templeton D M
Department of Clinical Biochemistry, University of Toronto, Ontario, Canada.
J Biol Chem. 1994 Jun 10;269(23):16046-53.
Non-transferrin-bound iron (NTBI) uptake occurs in a variety of cells by a saturable, specific and temperature-sensitive process. Our previous studies indicated that NTBI uptake by cardiac myocytes and Hep G2 cells was reversibly up-regulated by iron deposition. In the present work we have characterized this up-regulation and examined its mechanism by comparing the uptake of oxidized (Fe3+) and ascorbate-reduced (Fe2+) forms of iron. Iron loading markedly enhanced the uptake of iron both in the presence and absence of ascorbate, but the increment was greater when ascorbate was absent. This up-regulation is partially inhibited by actinomycin D and cycloheximide, indicating a requirement for protein synthesis. Uptake by the iron-loaded cells was less sensitive to thiol-alkylating agents and competing metal ions, but was more sensitive to proteolysis. Iron loading causes an increase in both Km and Vmax for uptake of both Fe2+ and Fe3+, although the values differ, suggesting distinct rate-limiting steps for uptake of Fe2+ and Fe3+. Consistent with this idea, uptake of the two ions showed differential sensitivity to thiol reagents, competing metal ions and monensin. The Fe(2+)-specific chelators bathophenanthroline disulfonate and ferrozine markedly inhibited iron uptake whether ascorbate was present or not, indicating that Fe3+ uptake is dependent on reduction to the ferrous state. This requirement for reduction was independent of the iron status of the cells, demonstrating that the process of up-regulation is not due to the appearance of a new mechanism for translocation of Fe3+ without reduction. Taken together, the evidence favors a model of NTBI transport where an obligate and rate-determining reduction of Fe3+ occurs prior to or during uptake, followed by translocation through an Fe2+ carrier. The distinct translocation mechanisms of uptake in the presence and absence of ascorbate suggest that exogenous Fe2+ does not access the carrier available to the nascent ferrous ion derived from the reductase and is consistent with close coupling between the reduction and the translocation processes. In iron-loaded cells with increased rates of NTBI transport, a similar mechanism prevails.
非转铁蛋白结合铁(NTBI)通过一种可饱和、特异性且对温度敏感的过程被多种细胞摄取。我们之前的研究表明,心肌细胞和Hep G2细胞对NTBI的摄取会因铁沉积而可逆地上调。在本研究中,我们对这种上调进行了表征,并通过比较氧化态(Fe3+)和抗坏血酸还原态(Fe2+)铁的摄取来研究其机制。铁负荷显著增强了在有和没有抗坏血酸存在时铁的摄取,但在没有抗坏血酸时增加幅度更大。这种上调被放线菌素D和环己酰亚胺部分抑制,表明需要蛋白质合成。铁负荷细胞的摄取对硫醇烷基化剂和竞争性金属离子不太敏感,但对蛋白水解更敏感。铁负荷导致摄取Fe2+和Fe3+的Km和Vmax均增加,尽管数值不同,这表明摄取Fe2+和Fe3+存在不同的限速步骤。与此观点一致,两种离子的摄取对硫醇试剂、竞争性金属离子和莫能菌素表现出不同的敏感性。Fe(2+)特异性螯合剂二磺酸邻二氮菲和亚铁嗪无论有无抗坏血酸均显著抑制铁摄取,表明Fe3+摄取依赖于还原为亚铁状态。这种还原需求与细胞的铁状态无关,表明上调过程并非由于出现了一种无需还原的Fe3+转运新机制。综上所述,证据支持一种NTBI转运模型,即Fe3+在摄取之前或摄取过程中发生必需的限速还原,随后通过Fe2+载体转运。在有和没有抗坏血酸存在时摄取的不同转运机制表明,外源性Fe2+无法进入还原酶产生的新生亚铁离子可利用的载体,这与还原和转运过程之间的紧密偶联一致。在NTBI转运速率增加的铁负荷细胞中,类似的机制也占主导。